HOME >> BIOLOGY >> NEWS
Vaccine to cope with viral diversity in HIV

The ability of HIV-1 to develop high levels of genetic diversity and acquire mutations to escape immune pressures contributes to our difficulties in producing a vaccine. David Nickle et al present here an efficient algorithm to develop vaccines that cope with the diversity of HIV or other variable pathogens.

This computational method clarifies and analyzes the variation found in the strains of the virus by describing the molecules which stimulate the immune response to HIV (immunogens) that have multiple forms of variable elements of the virus. These antigens compress the variation found in many viral strains into lengths suitable for vaccine immunogens. "We can capture 62% of the variation found in the Nef protein and 81% of the variation in the Gag protein into immunogens of three gene lengths", says Nickle.

These short-length immunogens are potentially useable in a vaccine, as they reflect the diversity of features in HIV-1 strains. These immunogens should elicit immune responses against high frequency viral strains as well as against most mutant forms of the virus.


'"/>

Contact: James Mullins
jmullins@u.washington.edu
206-732-6163
Public Library of Science
26-Apr-2007


Page: 1

Related biology news :

1. Vaccine trials inject hope into koalas future
2. Vaccine hope for malaria
3. Vaccine prevents prion disease in mice
4. Vaccine hope for sufferers of potentially fatal stomach bug
5. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
6. U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication
7. Vaccine-producing plant-factories
8. HPV Vaccine: Whats next
9. Vaccine shown effective against chancroid
10. Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax
11. Vaccine provides 100 percent protection against avian flu virus in animal study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vaccine cope with viral diversity HIV

(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
(Date:12/19/2014)... iLab Solutions, the global leader in ... Bryant as the new Director of Institutional Implementations and ... These two new leadership positions were created to support ... that iLab continues to meet the needs of its ... iLab has been deployed at over 450 core facilities ...
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... market will grow moderately through 2023 as the aging ... awareness of dental biomaterials all spur procedure volumes. Growth ... China and India ... procedures within reach for a larger proportion of the ...
(Date:12/17/2014)... 2014 The Activated Carbon Manufacturing ... is why IBISWorld updated its original industry research report. ... from an intensified focus on environmental policy. Over the ... standards for power plants and a range of other ... Industry Analyst Sarah Kahn, “a range of downstream industrial ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: